Doxycycline exposure during adolescence and future risk of non-affective psychosis and bipolar disorder: a total population cohort study.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
08 09 2021
08 09 2021
Historique:
received:
02
02
2021
accepted:
20
08
2021
revised:
04
08
2021
entrez:
9
9
2021
pubmed:
10
9
2021
medline:
12
10
2021
Statut:
epublish
Résumé
Doxycycline has been hypothesized to prevent development of severe mental illness (SMI) through the suppression of microglia, especially if administered during the intense synaptic pruning period of adolescence. However, results from register studies on potential benefits differ considerably. The aim of the present study was to determine whether doxycycline exposure during adolescence is associated with reduced SMI risk, and to investigate if a direct and specific causality is plausible. This is a Swedish national population register-based cohort study of all individuals born from 1993 to 1997, followed from the age of 13 until end of study at the end of 2016. The primary exposure was cumulative doxycycline prescription ≥3000 mg and outcomes were first diagnosis of non-affective psychosis (F20-F29) and first diagnosis of bipolar disorder (F30-F31). Causal effects were explored through Cox regressions with relevant covariates and secondary analyses of multilevel exposure and comparison to other antibiotics. We found no association between doxycycline exposure and risk of subsequent non-affective psychosis (adjusted hazard ratio (HR) 1.15, 95% CI 0.73-1.81, p = 0.541) and an increased risk of subsequent bipolar disorder (adjusted HR 1.95, 95% CI 1.49-2.55, p < 0.001). We do not believe the association between doxycycline and bipolar disorder is causal as similar associations were observed for other common antibiotics.
Identifiants
pubmed: 34497261
doi: 10.1038/s41398-021-01574-6
pii: 10.1038/s41398-021-01574-6
pmc: PMC8426383
doi:
Substances chimiques
Doxycycline
N12000U13O
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
468Subventions
Organisme : Wellcome Trust
ID : 211085/Z/18/Z
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
Chang CK, Hayes RD, Perera G, Broadbent MT, Fernandes AC, Lee WE, et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS ONE. 2011;6:e19590.
pubmed: 21611123
pmcid: 3097201
doi: 10.1371/journal.pone.0019590
Hannerz H, Borga P, Borritz M. Life expectancies for individuals with psychiatric diagnoses. Public Health. 2001;115:328–37.
pubmed: 11593442
doi: 10.1016/S0033-3506(01)00471-1
Laursen TM, Wahlbeck K, Hällgren J, Westman J, Ösby U, Alinaghizadeh H, et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS ONE. 2013;8:e67133.
pubmed: 23826212
pmcid: 3691116
doi: 10.1371/journal.pone.0067133
De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52–77.
doi: 10.1002/j.2051-5545.2011.tb00014.x
McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.
pubmed: 18480098
doi: 10.1093/epirev/mxn001
Hayes JF, Marston L, Walters K, King MB, Osborn D. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014. Br J Psychiatry. 2017;211:175–81.
pubmed: 28684403
pmcid: 5579328
doi: 10.1192/bjp.bp.117.202606
Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425–48.
pubmed: 24313570
doi: 10.1146/annurev-clinpsy-032813-153657
Brainstorm Consortium, Analysis of shared heritability in common disorders of the brain. Science. 2018;360:1–12.
Konopaske GT, Lange N, Coyle JT, Benes FM. Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder. JAMA Psychiatry. 2014;71:1323–31.
pubmed: 25271938
pmcid: 5510541
doi: 10.1001/jamapsychiatry.2014.1582
Radonjić NV, Hess JL, Rovira P, Andreassen O, Buitelaar JK, Ching C, et al. Structural brain imaging studies offer clues about the effects of the shared genetic etiology among neuropsychiatric disorders. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-020-01002-z .
Writing Committee for the Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Bipolar Disorder, et al. Virtual Histology of cortical thickness and shared neurobiology in 6 psychiatric disorders. JAMA Psychiatry.2021;78:47–63.
doi: 10.1001/jamapsychiatry.2020.2694
Neniskyte U, Gross CT. Errant gardeners: glial-cell-dependent synaptic pruning and neurodevelopmental disorders. Nat Rev Neurosci. 2017;18:658–70.
pubmed: 28931944
doi: 10.1038/nrn.2017.110
Inta D, Lang UE, Borgwardt S, Meyer-Lindenberg A, Gass P. Microglia activation and schizophrenia: lessons from the effects of minocycline on postnatal neurogenesis, neuronal survival and synaptic pruning. Schizophr Bull. 2017;43:493–6.
pubmed: 27352782
Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333:1456–8.
pubmed: 21778362
doi: 10.1126/science.1202529
Petanjek Z, Judaš M, Šimic G, Rasin MR, Uylings HB, Rakic P, et al. Extraordinary neoteny of synaptic spines in the human prefrontal cortex. Proc Natl Acad Sci USA. 2011;108:13281–6.
pubmed: 21788513
pmcid: 3156171
doi: 10.1073/pnas.1105108108
Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530:177–83.
pubmed: 26814963
pmcid: 4752392
doi: 10.1038/nature16549
Takahashi Y, Yu Z, Sakai M, Tomita H. Linking activation of microglia and peripheral monocytic cells to the pathophysiology of psychiatric disorders. Front Cell Neurosci. 2016;10:144.
pubmed: 27375431
pmcid: 4891983
doi: 10.3389/fncel.2016.00144
Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J Psychiatr Res. 1982;17:319–34.
pubmed: 7187776
doi: 10.1016/0022-3956(82)90038-3
Santa-Cecília FV, Socias B, Ouidja MO, Sepulveda-Diaz JE, Acuña L, Silva RL, et al. Doxycycline suppresses microglial activation by inhibiting the p38 MAPK and NF-kB signaling pathways. Neurotox Res. 2016;29:447–59.
pubmed: 26745968
doi: 10.1007/s12640-015-9592-2
Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA. 1998;95:15769–74.
pubmed: 9861045
pmcid: 28119
doi: 10.1073/pnas.95.26.15769
Barza M, Brown RB, Shanks C, Gamble C, Weinstein L. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob Agents Chemother. 1975;8:713–20.
pubmed: 1211925
pmcid: 429453
doi: 10.1128/AAC.8.6.713
Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharm Sci. 2004;25:609–12.
pubmed: 15530637
doi: 10.1016/j.tips.2004.10.001
Solmi M, Veronese N, Thapa N, Facchini S, Stubbs B, Fornaro M, et al. Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectr. 2017;22:415–26.
pubmed: 28181901
doi: 10.1017/S1092852916000638
Sellgren CM, Gracias J, Watmuff B, Biag JD, Thanos JM, Whittredge PB, et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat Neurosci. 2019;22:374–85.
pubmed: 30718903
pmcid: 6410571
doi: 10.1038/s41593-018-0334-7
Herrero-Zazo M, Brauer R, Gaughran F, Howard LM, Taylor D, Barlow DJ. Examining the potential preventative effects of minocycline prescribed for acne on the incidence of severe mental illnesses: a historical cohort study. J Psychopharmacol 2018;32:559–68.
pubmed: 29215319
doi: 10.1177/0269881117743483
Bienenfeld A, Nagler AR, Orlow SJ. Oral antibacterial therapy for acne vulgaris: an evidence-based review. Am J Clin Dermatol. 2017;18:469–90.
pubmed: 28255924
doi: 10.1007/s40257-017-0267-z
Del Rosso JQ. Oral doxycycline in the management of acne vulgaris: current perspectives on clinical use and recent findings with a new double-scored small tablet formulation. J Clin Aesthet Dermatol. 2015;8:19–26.
pubmed: 26155323
pmcid: 4479365
Jones MC, Koh JM, Cheong KH. Synaptic pruning in schizophrenia: does minocycline modulate psychosocial brain development? Bioessays. 2020;42:e2000046.
pubmed: 33448432
doi: 10.1002/bies.202000046
Le Moigne M, Bulteau S, Grall-Bronnec M, Gerardin M, Fournier JP, Jonville-Bera AP, et al. Psychiatric disorders, acne and systemic retinoids: comparison of risks. Expert Opin Drug Saf. 2017;16:989–95.
pubmed: 28657366
doi: 10.1080/14740338.2017.1344641
Ludot M, Mouchabac S, Ferreri F. Inter-relationships between isotretinoin treatment and psychiatric disorders: depression, bipolar disorder, anxiety, psychosis and suicide risks. World J Psychiatry 2015;5:222–7.
pubmed: 26110123
pmcid: 4473493
doi: 10.5498/wjp.v5.i2.222
Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24:659–67.
pubmed: 19504049
pmcid: 2773709
doi: 10.1007/s10654-009-9350-y
Ludvigsson JF, Almqvist C, Bonamy AK, Ljung R, Michaëlsson K, Neovius M, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 2016;31:125–36.
pubmed: 26769609
doi: 10.1007/s10654-016-0117-y
Ekbom A. The Swedish multi-generation register. Methods Mol Biol. 2011;675:215–20.
pubmed: 20949391
doi: 10.1007/978-1-59745-423-0_10
Ludvigsson JF, Svedberg P, Olén O, Bruze G, Neovius M. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol. 2019;34:423–37.
pubmed: 30929112
pmcid: 6451717
doi: 10.1007/s10654-019-00511-8
Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
pubmed: 21658213
pmcid: 3142234
doi: 10.1186/1471-2458-11-450
Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726–35.
pubmed: 16897791
doi: 10.1002/pds.1294
Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515–26.
doi: 10.1093/biomet/81.3.515
Nørgaard H, Søndergaard Pedersen H, Fenger-Grøn M, Mors O, Nordentoft M, Vestergaard M, et al. Increased use of primary care during 6 years of prodromal schizophrenia. Acta Psychiatr Scand. 2016;134:225–33.
pubmed: 27295520
doi: 10.1111/acps.12600
Wallace A, Isenberg K, York W, Shinde M, Barron J, Franchino-Elder J, et al. Detecting schizophrenia early: prediagnosis healthcare utilization characteristics of patients with schizophrenia may aid early detection. Schizophr Res. 2020;215:392–8.
pubmed: 31481337
doi: 10.1016/j.schres.2019.08.011
Köhler-Forsberg O, Petersen L, Gasse C, Mortensen PB, Dalsgaard S, Yolken RH, et al. A nationwide study in denmark of the association between treated infections and the subsequent risk of treated mental disorders in children and adolescents. JAMA Psychiatry. 2019;76:271–9.
pubmed: 30516814
doi: 10.1001/jamapsychiatry.2018.3428
Lambrichts S, Van Oudenhove L, Sienaert P. Antibiotics and mania: a systematic review. J Affect Disord. 2017;219:149–56.
pubmed: 28550767
doi: 10.1016/j.jad.2017.05.029
Yolken R, Adamos M, Katsafanas E, Khushalani S, Origoni A, Savage C, et al. Individuals hospitalized with acute mania have increased exposure to antimicrobial medications. Bipolar Disord. 2016;18:404–9.
pubmed: 27425597
pmcid: 5508736
doi: 10.1111/bdi.12416
Zareifopoulos N, Panayiotakopoulos G. Neuropsychiatric effects of antimicrobial agents. Clin Drug Investig. 2017;37:423–37.
pubmed: 28197902
doi: 10.1007/s40261-017-0498-z
Jorgensen L, Ahlbom A, Allebeck P, Dalman C. The Stockholm non-affective psychoses study (snaps): the importance of including out-patient data in incidence studies. Acta Psychiatr Scand. 2010;121:389–92.
pubmed: 19878139
doi: 10.1111/j.1600-0447.2009.01500.x
Saunders KEA, Goodwin GM. The course of bipolar disorder. Adv Psychiatr Treat. 2010;16:318–28.
doi: 10.1192/apt.bp.107.004903
Lazzarini M, Martin S, Mitkovski M, Vozari RR, Stühmer W, Bel ED. Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model. Glia. 2013;61:1084–100.
pubmed: 23595698
doi: 10.1002/glia.22496
Mattei D, Ivanov A, Ferrai C, Jordan P, Guneykaya D, Buonfiglioli A, et al. Maternal immune activation results in complex microglial transcriptome signature in the adult offspring that is reversed by minocycline treatment. Transl Psychiatry. 2017;7:e1120.
pubmed: 28485733
pmcid: 5534948
doi: 10.1038/tp.2017.80
Deakin B, Suckling J, Barnes T, Byrne K, Chaudhry IB, Dazzan P, et al. The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. Lancet Psychiatry. 2018;5:885–94.
pubmed: 30322824
pmcid: 6206257
doi: 10.1016/S2215-0366(18)30345-6